Background: The global burden of inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, is constantly rising. As IBDs significantly reduce patients’ quality of life, prevention and efficient treatment of IBDs are of paramount importance. Although the molecular mechanisms underlying IBD pathogenesis are still not completely understood, numerous studies indicate the essential role of oxidative stress in the progression of the diseases. Objective: The aim of this study was to investigate whether prophylactic administration of recombinant banana lectin (rBanLec) could positively affect antioxidative mechanisms in the colon and thus prevent or alleviate the severity of experimental colitis induced in C57BL/6 mice. Methods: The prophylactic potential of rBanLec, a mannose-binding lectin with immunomodulatory properties, was investigated in a model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in C57BL/6 mice. Mice received rBanLec at various doses (0.1, 1 and 10 μg/mL) before the induction of colitis. The severity of the disease was assessed by weight loss and reduction in colon length, and correlated with histopathological findings, cytokine milieu, and oxidative stress markers in the colon. Results: The obtained results revealed that pretreatment with a low dose of rBanLec (0.1 μg/mL) significantly reduced the severity of TNBS-induced colitis, as indicated by reduced weight loss, less severe histopathological damage, and a favorable anti-inflammatory cytokine milieu (increased IL-10 and TGFβ). In addition, rBanLec pretreatment improved the activity of antioxidant enzymes (SOD, CAT, and GST) and reduced markers of oxidative stress such as nitric oxide levels at the peak of the disease. In contrast, higher doses of rBanLec exacerbated inflammatory responses. Conclusions: Our findings indicate that at low doses rBanLec can alleviate the severity of colitis by modulating oxidative stress and promoting anti-inflammatory cytokine responses, positioning rBanLec as a potential candidate for treating IBDs.
Background: The Global Action Plan for Influenza Vaccines, launched by the World Health Organization in 2006, aimed to expand global manufacturing capacity, ensure equitable access to influenza vaccines, and reduce global vaccine shortages. The Institute of Virology, Vaccines and Sera “Torlak” was recognized as a partner and participated in a technology transfer programme to improve national production capabilities. Preclinical studies conducted in 2013 and 2014 provided comprehensive toxicological evidence supporting the safety of the trivalent influenza vaccine manufacturing platform. Nearly a decade later, this validated platform enabled the independent development of a quadrivalent influenza vaccine. Subsequent preclinical studies conducted in accordance with European Medicines Agency guidelines demonstrated preserved immunogenicity despite the inclusion of an additional antigen. Methods: Preclinical evaluation included standard safety and immunogenicity assessments in animal models. Safety assessment included evaluation of systemic parameters (general health status, leukocyte profile, blood biochemistry, and histopathology) and local reactions. Immunogenicity of both trivalent and quadrivalent formulations was assessed using haemagglutination inhibition and microneutralization assays. Results: No significant systemic or local adverse effects were observed. Both trivalent and quadrivalent formulations induced robust immune responses, with immunogenicity comparable to that of corresponding commercial vaccines. Conclusions: These findings confirm the safety profile and demonstrate strong immunogenicity for both the trivalent and quadrivalent formulations, supporting the successful establishment of a national influenza vaccine platform, contributing to increased pandemic preparedness and sustainable influenza vaccine production.